Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate

Derenzini, 2004, The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status, J Clin Pathol, 57, 755, 10.1136/jcp.2003.015917 Derenzini, 1990, Ultrastructural cytochemistry of the mammalian cell nucleolus, J Histochem Cytochem, 38, 1237, 10.1177/38.9.2201735 Hansen, 1990, Nucleolar organiser regions in hyperplastic and neoplastic prostatic tissue, Virchows Arch A Pathol Anat Histopathol, 417, 9, 10.1007/BF01600103 Omidi, 2001, Differentiation between prostatic carcinoma and nodular prostatic hyperplasia by AgNOR staining, Iran J Basic Med Sci, 4, 62 He, 2007, Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression, Cancer Res, 67, 8188, 10.1158/0008-5472.CAN-07-0418 Gamble, 2007, The hematoxylins and eosin, 121 Trere, 2000, AgNOR staining and quantification, Micron, 31, 127, 10.1016/S0968-4328(99)00069-4 Crocker, 1987, Nucleolar organizer regions in lymphomas, J Pathol, 151, 111, 10.1002/path.1711510203 Jackson, 2007, Immunohistochemical techniques, 433 Comstock, 2007, Impact of differential cyclin D1 expression and localisation in prostate cancer, Br J Cancer, 96, 970, 10.1038/sj.bjc.6603615 Karaburun Paker, 2001, Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer, Pathol Oncol Res, 7, 209, 10.1007/BF03032351 Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am J Surg Pathol, 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Asatiani, 2005, Targeted therapies for prostate cancer, Expert Opin Ther Targets, 9, 283, 10.1517/14728222.9.2.283 Gao, 2005, Chemistry and structural biology of androgen receptor, Chem Rev, 105, 3352, 10.1021/cr020456u Khan, 2008, Argyrophilic nucleolar organiser regions (AgNORs) pattern in different grades of transitional cell carcinoma of urinary bladder, Ann King Edw Med Uni, 14, 86 Chiusa, 1997, High and low risk prostate carcinoma determined by histologic grade and proliferative activity, Cancer, 79, 1956, 10.1002/(SICI)1097-0142(19970515)79:10<1956::AID-CNCR17>3.0.CO;2-U Ghazizadeh, 1991, Silver staining of nucleolar organizer regions in prostatic lesions, Histopathology, 19, 369, 10.1111/j.1365-2559.1991.tb00053.x Ahsan, 1992, Argyrophilic neocleolar organiser regions (AgNORs) in nodular hyperplasia and carcinoma of the prostate, Pak J Pathol, 3, 81 Hosni, 2010, Immunohistochemical Expression of cyclin D1 in Egyptian patients with prostatic car cinoma, Med J Cairo Univ, 78, 405 Chen, 2004, Molecular determinants of resistance to antiandrogen therapy, Nat Med, 10, 33, 10.1038/nm972 Drobnjak, 2000, Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone, Clin Cancer Res, 6, 1891 Ueda, 2001, Immunohistological evaluation of the expression of P27 and cyclin D1 in prostatic specimens, Nishinihon J Urol, 63, 246 Fleischmann, 2011, High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death, Virchows Arch, 458, 741, 10.1007/s00428-011-1084-z Shiraishi, 1998, A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers, Urol Int, 61, 90, 10.1159/000030295 Ozbek, 2000, Cyclin-D1 protooncogen expression in prostate cancer, Turk J Cancer, 30, 15